Corona Remedies made a remarkable debut on the stock market, opening with a significant premium. The company's Rs 655-crore IPO was massively oversubscribed, attracting strong interest from institutional and retail investors alike. This robust demand reflects confidence in Corona Remedies' solid financial performance, strategic focus on key healthcare areas, and promising earnings potential.
Corona Remedies makes stellar entry on Dalal Street with 38% premium over issue price
Published 4 hours ago
Source: timesofindia.indiatimes.com
Related Articles from timesofindia.indiatimes.com
24 minutes ago
'Just living my life': Elon Musk's ex-girlfriend claims he 'blocked' her
40 minutes ago
IPL Auction: Far from perfect — champions RCB look to plug gaps in Abu Dhabi
48 minutes ago
MGNREGA is now VB–G Ram G: What it is and how it’s different — key FAQs answered
1 hour ago
'Thoughtful analysis': Tharoor shares post comparing his ideas with Rahul; what it said
1 hour ago
Deadly pile-up on Delhi-Mumbai Expressway: Multiple vehicles collide due to dense fog; 4 dead
1 hour ago